Haemato-oncology experts discuss current considerations and future strategies for CAR T-cell therapies in patients with R/R MCL episode artwork

EPISODE · Jan 10, 2024 · 42 MIN

Haemato-oncology experts discuss current considerations and future strategies for CAR T-cell therapies in patients with R/R MCL

from touchPODCAST · host touchpodcast

touchIN CONVERSATION for touchHAEMATOLOGY Listen to a conversation between haemato-oncologists Dr Matthew Matasar and Dr Amitkumar Mehta, as they respond to questions submitted by the HCP audience and provide their expert insights on the current considerations and future strategies when managing the practicalities of CAR T-cell therapies in patients with relapsed or refractory mantle cell lymphoma. This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchhaematology.com

Episode metadata supplied by the publisher feed · Published Jan 10, 2024

Embed this episode

Ready to play

Haemato-oncology experts discuss current considerations and future strategies for CAR T-cell therapies in patients with R/R MCL

0:00 42:55

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 42 minutes long.

When was this touchPODCAST episode published?

This episode was published on January 10, 2024.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!